Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X about a paper by Thomas E. Stinchcombe et al. published in Lung Cancer Journal:
“What matters most when selecting a cancer therapy? What is the relative importance of efficacy vs safety?
In ALK+ NSCLC, there are several treatment options with tradeoffs requiring shared decision making.
Published in Lung Cancer Journal: a discrete choice experiment on patient and oncologist preferences. For both patients and oncologists, relative importance of treatment benefit outweighed that of avoiding AEs.
For patients, most important was stopping intracranial progression.
For oncologists, it was landmark PFS rate. Oncologists placed more importance on avoiding CNS AEs than patients did.
For patients, avoiding asthenia / fatigue was more important.
Certainly confounders with survey-based tools and a heterogeneous population, but very interesting findings and important reminder to avoid assumptions regarding what is most important for an individual person.”
Title: Patient and oncologist preferences for ALK+ advanced non-small cell lung cancer tyrosine kinase inhibitor treatments: a discrete choice experiment in the United States
Authors: Hannah Lea, Josh Coulter, Ken Culver, Joseph C. Cappelleri, Nada Rifi, Hui Lu, Matthew Quaife, Keila Meginnis, Gabriela S. Fernandez, Shailja Vaghela, Brett Hauber, Thomas E. Stinchcombe
You can read the full article in Lung Cancer Journal.
More posts featuring Stephen V Liu.